Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and...

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Genetics

Background:

• Thymic malignancies require a multidisciplinary approach for effective management.
• Systemic therapy is considered when local treatment is not feasible.
• Next-generation sequencing (NGS) guides the use of novel agents targeting specific signaling pathways.

Purpose of the Study:

• To review the current landscape of systemic agents for thymic malignancies.
• To highlight the role of NGS in identifying targetable pathways.
• To discuss challenges and future directions in systemic treatment strategies.

Main Methods:

• Review of Phase II trial data for systemic agents in thymic epithelial tumors.
• Analysis of NGS findings in thymomas and thymic carcinomas.
• Discussion of clinical challenges, including immune-related adverse events.

Main Results:

• PI3K/mTOR inhibitors, CDK inhibitors, and antiangiogenic agents demonstrate antitumor activity in advanced thymic tumors.
• NGS can identify targetable signaling pathways for personalized therapy.
• Immune checkpoint inhibitors present challenges due to frequent autoimmune comorbidities.

Conclusions:

• Systemic therapy plays a crucial role in managing thymic malignancies, particularly when local treatments are not an option.
• Personalized treatment strategies based on NGS are emerging.
• Further real-world data is essential to define optimal treatment sequences and patient selection for improved outcomes.